Beflandere S.L.C. Amendment #4

| AM | IENDMENT NO Calendar No | | |
|---|---|--|--|
| Pu | rpose: To condition drug exclusivity upon certain factors. | | |
| IN THE SENATE OF THE UNITED STATES—115th Cong., 1st Sess. | | | |
| | S. 934 | | |
| То | amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes. | | |
| R | eferred to the Committee on and ordered to be printed | | |
| | Ordered to lie on the table and to be printed | | |
| | Amendment intended to be proposed by Mr. Sanders | | |
| Viz: | | | |
| 1 | At the appropriate place, insert the following: | | |
| 2 | SEC CONDITIONS ON AWARD OF DRUG EXCLUSIVITY. | | |
| 3 | Subchapter E of chapter V of the Federal Food, | | |
| 4 | Drug, and Cosmetic Act (21 U.S.C. 360bbb et seq.) is | | |
| 5 | amended by adding at the end the following: | | |
| 6 | "SEC. 569D. CONDITIONS ON AWARD OF DRUG EXCLU- | | |
| 7 | SIVITY. | | |
| 8 | "(a) TERMINATION OF EXCLUSIVITY.—Notwith- | | |
| 9 | standing any other provision of this Act, any period of | | |
| 10 | exclusivity described in subsection (b) granted to a person | | |
| 11 | or assigned to a person on or after the date of enactment | | |

- 1 of this section with respect to a drug shall be terminated
- 2 if the person to which such exclusivity was granted or any
- 3 person to which such exclusivity is assigned commits a vio-
- 4 lation described in subsection (c)(1) with respect to such
- 5 drug.
- 6 "(b) Exclusivities Affected.—The periods of ex-
- 7 clusivity described in this subsection are those periods of
- 8 exclusivity granted under any of the following sections:
- 9 "(1) Clause (ii), (iii), or (iv) of section
- 10 505(c)(3)(E).
- 11 "(2) Clause (iv) of section 505(j)(5)(B).
- 12 "(3) Clause (ii), (iii), or (iv) of section
- 13 505(j)(5)(F).
- 14 "(4) Section 505A.
- 15 "(5) Section 505E.
- 16 "(6) Section 527.
- 17 "(7) Section 351(k)(7) of the Public Health
- 18 Service Act.
- 19 "(8) Any other provision of this Act that pro-
- vides for market exclusivity (or extension of market
- 21 exclusivity) with respect to a drug.
- 22 "(c) VIOLATIONS.—
- 23 "(1) IN GENERAL.—A violation described in
- this subsection is a violation of a law described in
- 25 paragraph (2) that results in—

| 1 | "(A) a criminal conviction of a person de- |
|----|--|
| 2 | scribed in subsection (a); |
| 3 | "(B) a civil judgment against a person de- |
| 4 | scribed in subsection (a); or |
| 5 | "(C) a settlement agreement in which a |
| 6 | person described in subsection (a) admits to |
| 7 | fault. |
| 8 | "(2) Laws described in |
| 9 | this paragraph are the following: |
| 10 | "(A) The provisions of this Act that pro- |
| 11 | hibit— |
| 12 | "(i) the adulteration or misbranding |
| 13 | of a drug; |
| 14 | "(ii) the making of false statements to |
| 15 | the Secretary or committing fraud; or |
| 16 | "(iii) the illegal marketing of a drug. |
| 17 | "(B) The provisions of subchapter III of |
| 18 | chapter 37 of title 31, United States Code |
| 19 | (commonly known as the 'False Claims Act'). |
| 20 | "(C) Section 287 of title 18, United States |
| 21 | Code. |
| 22 | "(D) The Medicare and Medicaid Patient |
| 23 | Protection and Program Act of 1987 (com- |
| 24 | monly known as the 'Antikickback Statute'). |

| 1 | "(E) Section 1927 of the Social Security |
|----|---|
| 2 | Act. |
| 3 | "(F) A State law against fraud comparable |
| 4 | to a law described in subparagraphs (A) |
| 5 | through (E). |
| 6 | "(d) DATE OF EXCLUSIVITY TERMINATION.—The |
| 7 | date on which the exclusivity shall be terminated as de- |
| 8 | scribed in subsection (a) is the date on which, as applica- |
| 9 | ble— |
| 10 | "(1) a final judgment is entered relating to a |
| 11 | violation described in subparagraph (A) or (B) of |
| 12 | subsection $(c)(1)$; or |
| 13 | "(2)(A) a settlement agreement described in |
| 14 | subsection $(e)(1)(C)$ is approved by a court order |
| 15 | that is or becomes final and nonappealable; or |
| 16 | "(B) if there is no court order approving a set- |
| 17 | tlement agreement described in subsection $(c)(1)(C)$, |
| 18 | a court order dismissing the applicable case, issued |
| 19 | after the settlement agreement, is or becomes final |
| 20 | and nonappealable. |
| 21 | "(e) Reporting of Information.—A person de- |
| 22 | scribed in subsection (a) that commits a violation de- |
| 23 | scribed in subsection $(c)(1)$ shall report such violation to |
| 24 | the Secretary no later than 30 days after the date that— |

| 1 | "(1) a final judgment is entered relating to a |
|----|--|
| 2 | violation described in subparagraph (A) or (B) of |
| 3 | subsection $(c)(1)$; or |
| 4 | "(2)(A) a settlement agreement described in |
| 5 | subsection (c)(1)(C) is approved by a court order |
| 6 | that is or becomes final and nonappealable; or |
| 7 | "(B) if there is no court order approving a set- |
| 8 | tlement agreement described in subsection (c)(1)(C), |
| 9 | a court order dismissing the applicable case, issued |
| 10 | after the settlement agreement, is or becomes final |
| 11 | and nonappealable.". |